Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SAR443820 in multiple sclerosis assessing serum neurofilament levels
2022-000049-34Phase 2Active
- Sponsor
- Sanofi
- Start
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing SAR443820 with Placebo (2 arms). Primary endpoint: Week 48 serum neurofilament levels relative to baseline. Started May 2022; status: active.
02
Drugs
oditrasertib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2022-000049-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000049-34.